Skip to main content
Silvio Inzucchi, MD, Endocrinology, New Haven, CT

Silvio Edward Inzucchi MD

Adrenal Disease, Diabetes, Pituitary Disorders & Neuroendocrinology


Professor of Medicine, Yale University

Join to View Full Profile
  • 789 Howard Avenue 2nd FloorDana BuildingNew Haven, CT 06510

Dr. Inzucchi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Yale-New Haven Medical Center
    Yale-New Haven Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 1992 - 1994
  • Yale-New Haven Medical Center
    Yale-New Haven Medical CenterResidency, Internal Medicine, 1985 - 1987
  • Harvard Medical School
    Harvard Medical SchoolClass of 1985

Certifications & Licensure

  • CT State Medical License
    CT State Medical License 1987 - 2025
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Endocrinology, Diabetes and Metabolism
    American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2008-2014
  • New York Magazine: Top Doctors Castle Connolly, 2007-2014
  • Top Doctors: New York Metro Area Castle Connolly, 2006-2014
  • Join now to see all

Publications & Presentations

PubMed

Journal Articles

  • Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial  
    Silvio Inzucchi, MD, Journal of the American Society of Nephrology
  • Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients  
    Erin A Bohula, Stephen D Wiviott, Benjamin M Scirica, Darren K McGuire, Marc S Sabatine, Marc P Bonaca, Christian T Ruff, Silvio E Inzucchi, The New England Journal of Medicine
  • Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients  
    Christina L. Fanola, Darren K. McGuire, Silvio E. Inzucchi, Erin A. Bohula, The New England Journal of Medicine

Lectures

  • Reduction in Albuminuria with Dapagliflozin Cannot Be Predicted by Baseline Clinical Characteristics or Changes in Most Other Risk Markers 
    American Heart Association, Scientific Sessions 2010, Chicago, Illinois, USA
  • Reduction in Albuminuria with Dapagliflozin Cannot Be Predicted by Baseline Clinical Characteristics or Changes in Most Other Risk Markers 
    Scientific Sessions 2008, New Orleans, Louisiana, USA
  • Reduction in Albuminuria with Dapagliflozin Cannot Be Predicted by Baseline Clinical Characteristics or Changes in Most Other Risk Markers 
    Scientific Sessions 2010, Chicago, Illinois, USA
  • Join now to see all

Other

Press Mentions

  • SGLT2 Inhibitors Cut AFib Risk in Real-Word Analysis
    SGLT2 Inhibitors Cut AFib Risk in Real-Word AnalysisJune 13th, 2022
  • SGLT2 Inhibitors Cut AFib Risk in Real-Word Analysis
    SGLT2 Inhibitors Cut AFib Risk in Real-Word AnalysisJune 13th, 2022
  • Explaining Insulin Resistance, and How to Reverse It
    Explaining Insulin Resistance, and How to Reverse ItOctober 25th, 2021
  • Join now to see all

Grant Support

  • GRADE TrialNIDDK2013–2020
  • IRIS TrialNINDS2004–2016
  • Dosage According To IGF1 Response In Growth Hormone DefiNational Center For Research Resources2000–2001
  • Effects Of Troglitazone And Metformin On Glucose MetabolismNational Center For Research Resources1996–1999
  • Ovine CRH In Evaluation Of Cushing SyndromeNational Center For Research Resources1997
  • Endocrine Evaluation Of Patients With Diseases Of The PituitaryNational Center For Research Resources1996–1997
  • Effects Of Growth Hormone Replacement In GH Deficient AdultsNational Center For Research Resources1996

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: